Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE